Oxyntomodulin attenuates exendin-4-induced hypoglycemia in cattle

Domestic Animal Endocrinology

Volumn 44, Issue 2, 2013, Pages 70-80

  ThanThan, S ^a   Asada, Y ^a   Saito, T ^a   Ochiiwa, K ^a   Zhao, H ^a   Yannaing, S ^a   Kuwayama, H ^a  

^a OBIHIRO UNIVERSITY OF AGRICULTURE AND VETERINARY MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; INSULIN; OXYNTOMODULIN; PEPTIDE; VENOM;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD; CATTLE; CATTLE DISEASE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HYPOGLYCEMIA; MALE; RADIOIMMUNOASSAY;

ANIMALS; BLOOD GLUCOSE; CATTLE; CATTLE DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HYPOGLYCEMIA; INSULIN; MALE; OXYNTOMODULIN; PEPTIDES; RADIOIMMUNOASSAY; VENOMS;

ANIMALIA; BOS; BOVIDAE;

EID: 84871932143     PISSN: 07397240     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.domaniend.2012.09.003     Document Type: Article

References (36)

1. Samols E., Marri G., Marks V. Promotion of insulin secretion by glucagon. Lancet 1965, 2:415-416.
2. Johnson M.E., Das N.M., Butcher F.R., Fain J.N. The regulation of gluconeogenesis in isolated rat liver cells by glucagon, insulin, dibutyryl cyclic adenosine monophosphate, and fatty acids. J Biol Chem 1972, 247:3229-3235.
3. Holst J.J. Interaction of hepatocyte membrane receptors with pancreatic and gut glucagon. Glucagon: Its Role in Physiology and Clinical Medicine 1977, 287-303. Springer, New York. P.P. Foa, J.S. Baja, N.L. Foa (Eds.).
4. Jarrousse C., Bataille D., Jeanrenaud B. A pure enteroglucagon, oxyntomodulin (glucagon 37), stimulates insulin release in perfused rat pancreas. Endocrinology 1984, 115:102-105.
5. ThanThan S., Zhao H., Yannaing S., Ishikawa T., Kuwayama H. Oxyntomodulin increases the concentrations of insulin and glucose in plasma but does not affect ghrelin secretion in Holstein cattle under normal physiological conditions. Domest Anim Endocrinol 2010, 39:163-170.
6. Collie N.L., Zhu Z., Jordan S., Reeve J.R. Oxyntomodulin stimulates intestinal glucose uptake in rats. Gastroenterology 1997, 112:1961-1970.
7. Stümpel F., Scholtka B., Jungermann K. A new role for enteric glucagon-37: acute stimulation of glucose absorption in rat small intestine. FEBS Lett 1997, 410:515-519.
8. Baggio L.L., Huang Q., Brown T.J., Drucker D.J. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 2004, 127:546-558.
9. Wynne K., Bloom S.R. The role of oxyntomodulin and peptide tyrosine-tyrosine (PYY) in appetite control. Nat Clin Pract Endocrinol Metab 2006, 2:612-620.
10. Hui H., Yu R., Bousquet C., Perfetti R. Transfection of pancreatic-derived beta-cells with a minigene encoding for human glucagon-like peptide-1 regulates glucose-dependent insulin synthesis and secretion. Endocrinology 2002, 143:3529-3539.
11. Nathan D.M., Schreiber E., Fogel H., Mojsov S., Habener J.F. Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 1992, 15:270-276.
12. Nauck M.A., Kleine N., Ørskov C., Holst J.J., Willms B., Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993, 36:741-744.
13. Villanueva-Peñacarrillo M.L., Puente J., Redondo A., Clemente F., Valverde I. Effect of GLP-1 treatment on GLUT2 and GLUT4 expression in type 1 and type 2 rat diabetic models. Endocrine 2001, 15:241-248.
14. Park J.H., Kim S.J., Park S.H., et al. Glucagon-like peptide-1 enhances glucokinase activity in pancreatic β-cells through the association of Epac2 with Rim2 and Rab3A. Endocrinology 2012, 153:574-582.
15. Kieffer T.J., McIntosh C.H., Pederson R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995, 136:3585-3596.
16. Vilsbøll T., Agersø H., Krarup T., Holst J.J. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003, 88:220-224.
17. Kolterman O.G., Kim D.D., Shen L., et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005, 62:173-181.
18. Agersø H., Jensen L.B., Elbrønd B., Rolan P., Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002, 45:195-202.
19. Eng J., Kleinman W.A., Singh L., Singh G., Raufman J.P. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992, 267:7402-7405.
20. Parkes D.G., Pittner R., Jodka C., Smith P., Young A. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 2001, 50:583-589.
21. Greig N.H., Holloway H.W., De Ore K.A., et al. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia 1999, 42:45-50.
22. Fineman M.S., Bicsak T.A., Shen L.Z., et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003, 26:2370-2377.
23. Tourrel C., Bailbé D., Meile M.J., Kergoat M., Portha B. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 2001, 50:1562-1570.
24. Arnés L., Moreno P., Nuche-Berenguer B., Valverde I., Villanueva-Peñacarrillo M.L. Effect of exendin-4 treatment upon glucose uptake parameters in rat liver and muscle, in normal and type 2 diabetic state. Regul Pept 2009, 153:88-92.
25. Dhanesha N., Joharapurkar A., Shah G., et al. Exendin-4 activates glucokinase. J Diabetes 23 February 2012, epub ahead of print, doi:10.1111/j.1753-0407.2012.00193.x.
26. Berg J.K., Shenouda S.K., Heilmann C.R., Gray A.L., Holcombe J.H. Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study. Diabetes Obes Metab 2011, 13:982-989.
27. ThanThan S., Saito T., Yannaing S., Zhao H., Nakashima K., Kuwayama H. Glucagon-like peptide-1 inhibits insulinotropic effects of oxyntomodulin and glucagon in cattle. Domest Anim Endocrinol 2012, 42:155-164.
28. ThanThan S., Mekaru C., Seki N., et al. Endogenous ghrelin released in response to endothelin stimulates growth hormone secretion in cattle. Domest Anim Endocrinol 2010, 38:1-12.
29. McConahey P.J., Dixon F.J. Radioiodination of proteins by the use of the chloramine-T method. Methods in Enzymology 1980, 210-213. Academic Press, New York. H.V. Vunakis, J.J. Langone (Eds.).
30. 125I-labeled secretin of high specific radioactivity. Anal Biochem 1975, 69:34-42.
31. Eng J., Andrews P.C., Kleinman W.A., Singh L., Raufman J.P. Purification and structure of exendin-3, a new pancreatic secretagogue isolated from Heloderma horridum venom. J Biol Chem 1990, 265:20259-20262.
32. Fehmann H.C., Jiang J., Schweinfurth J., Wheeler M.B., Boyd A.E., Göke B. Stable expression of the rat GLP-I receptor in CHO cells: activation and binding characteristics utilizing GLP-I(7-36)-amide, oxyntomodulin, exendin-4, and exendin(9-39). Peptides 1994, 15:453-456.
33. Baldissera F.G.A., Holst J.J., Knuhtsen S., Hilsted L., Nielsen O.V. Oxyntomodulin (glicentin-(33-69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs. Regul Pept 1988, 21:151-166.
34. Parlevliet E.T., Heijboer A.C., Schröder-van der Elst J.P., et al. Oxyntomodulin ameliorates glucose intolerance in mice fed a high-fat diet. Am J Physiol Endocrinol Metab 2008, 294:E142-E147.
35. Gilor C., Graves T.K., Gilor S., Ridge T.K., Rick M. The GLP-1 mimetic exenatide potentiates insulin secretion in healthy cats. Domest Anim Endocrinol 2011, 41:42-49.
36. Montrose-Rafizadeh C., Yang H., Rodgers B.D., Beday A., Pritchette L.A., Eng J. High potency antagonists of the pancreatic glucagon-like peptide-1 receptor. J Biol Chem 1997, 272:21201-21206.